4Sc AG
XETRA:VSC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
4
|
4Sc AG
XETRA:VSC
|
DE |
|
Japan Excellent Inc
TSE:8987
|
JP |
|
Wishbone Gold PLC
LSE:WSBN
|
GI |
|
G
|
Guangdong Hotata Technology Group Co Ltd
SSE:603848
|
CN |
|
G
|
G City Ltd
TASE:GCT
|
IL |
|
Saudi Arabian Oil Co
SAU:2222
|
SA |
|
M
|
Makarony Polskie SA
WSE:MAK
|
PL |
|
Sinch AB (publ)
STO:SINCH
|
SE |
|
Universe Group PLC
LSE:UNG
|
UK |
|
Paragon Banking Group PLC
LSE:PAG
|
UK |
4Sc AG
4SC AG is a clinical-stage biopharmaceutical company, which engages in the development of small molecule drugs that target key indications in cancer. The company is headquartered in Planegg, Bayern and currently employs 39 full-time employees. The company went IPO on 2008-02-25. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
4SC AG is a clinical-stage biopharmaceutical company, which engages in the development of small molecule drugs that target key indications in cancer. The company is headquartered in Planegg, Bayern and currently employs 39 full-time employees. The company went IPO on 2008-02-25. The Company’s product pipeline includes several anti-cancer drugs, which are in various stages of preclinical and clinical development. Its main products are Resminostat, an orally administered histone deacetylase (HDAC) inhibitor for the treatment of a broad spectrum of oncology indications, both in monotherapy in combination with other anti-cancer drugs; 4SC-202, an orally administered small molecule and epigenetic modulator that inhibits the enzymes lysine-specific demethylase 1 (LSD1) and histone deacetylase (HDAC) 1, 2, 3, and 4SC-208, a small molecule that targets two kinases for Hedgehog/GLI signaling.
This earnings call has not been analyzed yet.
If you’d like us to analyze this earnings call, click the "Request Earnings Call Analysis" button below.
